Ligand validation:8EC4

TSL: TRANS-ENAMINE INTERMEDIATE OF SULBACTAM

TSL is a Ligand Of Interest in 8EC4 designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8EC4_TSL_A_302	31%	5%	0.209	0.878	1.66	3.54	2	1	2	0	100%	0.837
8EC4_TSL_B_302	30%	5%	0.188	0.849	1.66	3.51	2	1	0	0	100%	1
8EC4_TSL_D_302	24%	6%	0.218	0.849	1.66	3.35	2	2	0	0	100%	1
8EC4_TSL_C_302	7%	5%	0.305	0.769	1.7	3.6	2	2	0	0	100%	0.807
7A72_TSL_A_501	73%	44%	0.106	0.931	1.46	0.72	2	-	1	0	100%	1
8GCX_TSL_B_302	63%	5%	0.181	0.977	1.69	3.68	2	3	2	0	100%	1
6H2K_TSL_B_501	60%	21%	0.12	0.906	1.23	2.05	-	2	3	0	100%	1
8EBR_TSL_B_302	25%	5%	0.244	0.882	1.67	3.65	2	3	0	0	100%	1
8BTV_TSL_A_301	18%	31%	0.193	0.777	1.3	1.45	1	2	3	0	100%	1
6J2B_TSL_A_301	48%	55%	0.141	0.882	1.38	0.4	1	-	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.